
Release date: 2026-02-02 17:03:27 Article From: Lucius Laos Recommended: 9
Take elacestrant daily and always follow the guidance of your medical team strictly.
Elacestrant can significantly prolong the progression-free survival (PFS) of patients with ESR1-mutated metastatic breast cancer.
Specific Efficacy: Elacestrant is specifically indicated for ESR1-mutated metastatic breast cancer, and it can double the duration of progression-free survival in patients—meaning the time during which the cancer does not spread, grow or worsen.
Data Comparison: After the start of treatment, the median progression-free survival (mPFS) of patients in the elacestrant group was 3.8 months, while that of patients receiving other commonly used hormonal therapies was only 1.9 months (individual efficacy may vary).
Term Explanation: Median progression-free survival (mPFS) is a time measurement index in clinical trials, referring to the time point at which half of the patients in the trial experience no disease progression.
Main Side Effects: Elacestrant may cause elevated lipid levels in the blood (hypercholesterolemia and hypertriglyceridemia). Medical staff will conduct lipid tests before and during treatment to monitor relevant indicators.
Health Conditions to Inform Medical Staff of Before Taking:
A history of liver disease.
Current pregnancy or pregnancy planning (elacestrant may cause fetal harm).
Findings from Clinical Trials: Most side effects are mild to moderate, and most patients do not need additional antiemetic medications while taking elacestrant.
Additional Recommendations for Women and Men of Childbearing Potential:
Female patients: A pregnancy test may be required before treatment; effective contraceptive measures should be taken during treatment and for one week after the last dose; if pregnancy occurs or is suspected during treatment, medical staff should be informed immediately.
Male patients with female partners of childbearing potential: Effective contraceptive measures should be taken during treatment and for one week after the last dose.
Take elacestrant at approximately the same time every day.
If a dose is missed, it can be taken within 6 hours; if more than 6 hours have passed, skip the missed dose and resume the normal dosing schedule the next day.
Do not adjust the dose or stop taking the medication on your own unless instructed otherwise by a healthcare provider.
Taking elacestrant with food may help reduce feelings of nausea and vomiting.
Swallow the tablets whole; do not chew, crush or split them.
Elacestrant can be taken anywhere (at home or while out).
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:802025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3732024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:712025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:932025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:872025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1022025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:992025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:992025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: